The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 140 affiliates and more than 46,000 employees. The company's key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease, cerebrovascular disease, oncology, diabetes and hepatitis. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Research Grants 26 show all


$2.4M
1987

$8.4M
2010

$10.7M
2015

$8.5M
2016

$0
2018

Publications 4 show all

  • 1
    Anti-Inflammatory Agents, Non-Steroidal/pharmacology
  • 1
    Cyclooxygenase Inhibitors/pharmacology
  • 1
    Gram-Negative Bacteria/isolation & purification
  • 1
    Gram-Negative Bacterial Infections/veterinary
  • 1
    Prostaglandin-Endoperoxide Synthases/physiology
  • 1
    Swine Diseases/diagnosis

Patents 34,716show all

  • 4,700
    C07D - Heterocyclic compounds
  • 4,643
    A61K - Preparations for medical, dental, or toilet purposes
  • 2,161
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 1,849
    C07K - Peptides
  • 1,779
    C12N - Microorganisms or enzymes
  • 1,660
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 847
    C07C - Acyclic or carbocyclic compounds
  • 688
    C07H - Sugars
  • 600
    A61M - Devices for introducing media into, or onto, the body
  • 353
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Clinical Trials 178show all

89Phase 367N/A11Phase 411Other

Contact Information

Ingelheim am Rhein
Germany